A New Lease on Life: Successful CD7 CAR-T Therapy Bridges to Transplant for 15-Year-Old with Relapsed T-ALL

At just 15 years old, a boy’s life was turned upside down by a diagnosis of T-cell acute lymphoblastic leukemia (T-ALL), marked by a series of challenging treatments and setbacks. Despite undergoing chemotherapy and an allogeneic stem cell transplant, he faced early relapse and complications. However, through the dedication of his family and the expertise of the medical team at BIOOCUS, he received CD7 CAR-T therapy, ultimately leading to a life-saving second transplant.

Initially diagnosed in December 2020, the patient achieved complete remission after multiple rounds of chemotherapy. However, just three months post-transplant, he experienced a relapse, compounded by central nervous system involvement. Standard treatments proved ineffective, leaving the family searching for alternatives.

In October 2021, the patient was admitted to BIOOCUS, where he received further chemotherapy to reduce the tumor burden before being treated with CD7 CAR-T cells. Unfortunately, the first CAR-T attempt was unsuccessful, prompting the medical team to consider the ongoing clinical trial for CD7 universal CAR-T therapy.

Universal CAR-T therapy offers significant advantages, including the ability to use T-cells derived from healthy donors, allowing for quicker access to treatment without the need for personalized customization. This was crucial for the patient, who had a high tumor burden and could not provide enough cells for traditional autologous CAR-T therapy.

On December 2, 2021, the patient received the CD7 universal CAR-T cells. After the treatment, he initially faced challenges, including fever and fatigue. However, with supportive care, his condition stabilized, and follow-up assessments revealed a remarkable complete remission, with no evidence of minimal residual disease (MRD).

Following this successful treatment, the patient underwent a second transplant, which went smoothly. Now, nearly three years later, he is thriving, resuming normal activities and enjoying life, much to the relief of his family.

Dr. Zhang Xian, head of the hematology department at BIOOCUS, emphasizes the importance of CD7 universal CAR-T therapy as a critical option for patients who cannot undergo traditional treatments. This case highlights the promising future of CAR-T therapies in treating T-cell malignancies, especially for those with relapsed forms of leukemia.

As research advances, the potential of CAR-T therapies continues to expand, offering new hope to patients battling challenging conditions like T-ALL. BIOOCUS remains committed to pioneering innovative treatments and improving patient outcomes through ongoing clinical research.

For more information about our CAR-T therapies and how they can help you or a loved one, please contact BIOOCUS.